LifeSci Capital initiated coverage of MBX Biosciences (MBX) with an Outperform rating and $75 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- Options Volatility and Implied Earnings Moves Today, March 23, 2026
- MBX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MBX Biosciences Advances Avail Phase 2 Trial in Hypoparathyroidism: What Investors Should Watch
- MBX Biosciences files automatic mixed securities shelf
- MBX Biosciences reports Q4 EPS (49c), consensus (63c)